ArticleChemistry & biodiversity2026
Cytotoxic and Antileishmanial Potential of Pilocarpus microphyllus Essential Oil: In Vitro and In Silico Study.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytotoxic and Antileishmanial Potential of Pilocarpus microphyllus Essential Oil: In Vitro and In Silico Study.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The essential oil of Pilocarpus microphyllus (jaborandi) (EOJ), a species traditionally recognized for its alkaloid-based pharmacological properties, remains poorly investigated despite its richness in bioactive terpenes. In this study, the chemical profile of EOJ obtained from fresh and dried leaves was determined by gas chromatography-mass spectrometry, revealing 24 constituents, predominantly γ-cadinene (23.6%) and trans-caryophyllene (22.9%). Antifungal activity was observed against Cryptococcus neoformans (minimum inhibitory concentration: 149-2395 µg/mL), while antileishmanial potential was confirmed against Leishmania amazonensis promastigotes (half-maximal inhibitory concentration [IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.